Anti-inflammatory particles

Patent metadata

Field	Value
Publication number	US-10154977-B2
Application number	US-201214006118-A
Country	US
Kind code	B2
Filing date	Mar 23, 2012
Priority date	Mar 25, 2011
Publication date	Dec 18, 2018
Grant date	Dec 18, 2018

Abstract

Described herein are compositions and methods relating to particles comprising at least one component of a cellular-derived microparticle. Aspects of technology described herein relate to compositions and methods for treating inflammation, wounds, and pain.

First claim

What is claimed herein is:

1. An in vitro anti-inflammatory particle comprising:
at least one component of a humanized cellular-derived microparticle selected from the group consisting of: Resolvin D1, Resolvin D2, Resolvin D3, Resolvin D5, Resolvin D6, Maresin 1, and Protectin D 1;
and at least one anti-inflammatory therapeutic agent;
wherein the at least one component of a humanized cellular-derived microparticle has a pro-resolving anti-inflammatory property.

2. The anti-inflammatory particle of claim 1 , wherein the humanized cellular-derived microparticle is generated in vitro by contacting a cell with a leukocyte agonist.

3. The anti-inflammatory particle of claim 2 , wherein the leukocyte agonist is selected from the group consisting of:
IL-8; fMLP; IL-4; zymosan; LPS; leukotriene B4; and C5a.

4. The anti-inflammatory particle of claim 1 , wherein the agent comprises about 0.01 wt % to about 99 wt % of the particle.

5. The anti-inflammatory particle of claim 1 , wherein the particle comprises from about 0.1 fg to about 1000 fg of the agent.

6. The anti-inflammatory particle of claim 1 , wherein the particle comprises from about 50 fg to about 150 fg of the agent.

7. The anti-inflammatory particle of claim 1 , wherein the particle is of a size from about 100 nm to about 1.5 μm in diameter.

8. The anti-inflammatory particle of claim 1 , wherein the at least one component of the cellular-derived microparticle comprises analogs and mimetics thereof.

9. The anti-inflammatory particle of claim 1 , wherein the anti-inflammatory property of the anti-inflammatory particle is capable of decreasing at least one of a sign, a condition, and/or a symptom of inflammation.

10. The anti-inflammatory particle of claim 9 , wherein the at least one of a sign, a condition, and/or a symptom of inflammation comprises an inflammatory condition of a skin, an inflammatory condition of a lung, an inflammatory condition of a joint, an inflammatory condition of a gut, an inflammatory condition of an eye, an inflammatory condition of a endocrine system, an inflammatory condition of a cardiovascular system, an inflammatory condition of a kidney, an inflammatory condition of a liver, an inflammatory condition of a central nervous system, and/or a sepsis-associated condition.

Assignees

• Serhan Charles N
• Norling Lucy V
• Spite Matthew
• Dalli Jesmond P
• Brigham & Womens Hospital Inc

Inventors

• Serhan Charles N
• Norling Lucy V
• Spite Matthew
• Dalli Jesmond P

Classifications

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61K35/12

  Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title

• A61K51/1244

  microparticles or nanoparticles, e.g. polymeric nanoparticles · CPC title

• A61P19/00

  Drugs for skeletal disorders · CPC title

• A61K31/202 Primary

  having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557) · CPC title